Speaker: Brian Slomovitz, MD
This virtually live ASCO program provides oncologists, APPs, nurses, pharmacists, and clinicians with a comprehensive update on the rapidly evolving treatment landscape of ovarian cancer. Participants will explore the structure, mechanism of action, and therapeutic rationale behind recently approved and emerging agents, including antibody-drug conjugates (ADCs), glucocorticoid receptor modulators, and bispecific antibodies. Through a detailed analysis of the latest clinical trial safety and efficacy data alongside updated guidelines, the session focuses on practical strategies for integrating these novel therapies into clinical practice using shared decision-making. Additionally, the program offers expert guidance on proactively monitoring and managing unique adverse events, ensuring clinicians are equipped to optimize patient outcomes and safety in the modern era of precision oncology.
The proposed education will be designed to meet the educational needs of gynecologic and medical oncologists, nurses, pharmacists, advanced practice providers, and other clinicians involved in the treatment of patients with gynecologic malignancies.